VistaGen Therapeutics (VTGN) Q3 2026 earnings summary

Executive summary

• Completed randomized portion of PALISADE-3 Phase 3 trial in social anxiety disorder; topline results from PALISADE-4 expected in H1 2026, with operational refinements implemented.

• Ongoing AI/ML analysis to optimize statistical models and understand placebo/active drug response across PALISADE studies.

• Open-label extensions of PALISADE-3 and PALISADE-4 continue to assess safety and real-world use of fasedienol.

• USAN adoption for PH80 (rafisolone) and IND submission planned for menopause-related vasomotor symptoms in H1 2026.

• Appointment of Nick Tressler as Chief Financial Officer in December 2025.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $61.8 million as of December 31, 2025.

• Net loss was $18.9 million for the quarter and $53.4 million for the nine months ended December 31, 2025.

• R&D expenses increased to $14.2 million for the quarter, mainly due to clinical development of fasedienol.

• General and administrative expense rose to $5.6 million for the quarter, primarily due to higher consulting and professional fees.

• Revenue was $0.3 million for the quarter and $0.8 million for the nine months, primarily from sublicense and collaboration agreements.

Outlook and guidance

• On track to complete PALISADE-4 as guided, with topline results expected in H1 2026.

• IND for rafisolone planned for submission in the first half of 2026 to support further Phase 2 development.

• Substantial doubt exists about the ability to continue as a going concern beyond twelve months from the financial statement issuance date, absent additional financing.

• Research and development and general and administrative expenses are expected to decrease due to cash preservation measures, but may increase if PALISADE-4 is successful and the program advances toward NDA submission.

• Plans to seek additional capital through equity, debt, grants, or strategic partnerships.